A股CRO概念持续拉升，睿智医药涨停，美迪西涨超8%，成都先导涨近7%，联化科技、凯莱英等跟 涨。 ...

证券代码：688202 证券简称：美迪西 公告编号：2025-036 上海美迪西生物医药股份有限公司 关于以集中竞价交易方式回购公司股份比例达到 1% 暨回购进展公告 回购方案实施期限 待公司股东大会审议通过后 6 个月 预计回购金额 5,000万元~10,000万元 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： √减少注册资本 回购方案首次披露日 2024/12/28，由公司实际控制人、时任董事长陈金 章先生，实际控制人、时任董事、总经理 √用于员工持股计划或股权激励 CHUN-LIN CHEN 先生提议 回购用途 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，回购股份占公司总股本的比例 每增加 1%的，应当在事实发生之日起 3 个交易日内予以披露。现将公司回购股份 进展情况公告如下： 截至 2025 年 5 月 28 日，公司通过上海证券交易所系统以集中竞价交易方式 已累计回购公司股份 1,346,910 股，已回购股份占公司总股本 ...

关于以集中竞价交易方式回购公司股份比例达到 1% 暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688202 证券简称：美迪西 公告编号：2025-036 上海美迪西生物医药股份有限公司 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定及公司回购股份方案，在回购期限内根 据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进展情况及时 履行信息披露义务，敬请广大投资者注意投资风险。 | 回购方案首次披露日 | 2024/12/28，由公司实际控制人、时任董事长陈金 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 章 先 生 ， 实 制 人 董 事 、 总 经 理 | 际 | 控 | 、 | 时 | 任 | | | CHUN-LIN CHEN 先生提议 | | | | | | | 回购方案实施期限 | 待公司股东大会审议通过后 个月 6 | | ...

| 证券代码：688202 证券简称：美迪西 公告编号：2025-035 | | | | | | | --- | --- | --- | --- | --- | --- | | 上海美迪西生物医药股份有限公司 | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | 重要内容提示： | | | | | | | ? 本次会议是否有被否决议案：无 | | | | | | | 一、 会议召开和出席情况 | | | | | | | （一） 股东大会召开的时间：2025 月 13 | 年 5 | 日 | | | | | （二） 股东大会召开的地点：上海市浦东新区川大路 号上海美迪西生物医 | | | 585 | | | | 药股份有限公司会议室 | | | | | | | （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | | | | | | | 其持有表决权数量的情况： | | | | | | | 普通股股东人数 77 | | | | ...

北京安理（上海）律师事务所 关于 上海美迪西生物医药股份有限公司 法律意见书 上海市长宁区长宁路 1189 号长宁来福士广场 T2 办公楼 17 层 03 单元 安理律师事务所 法律意见书 北京安理（上海）律师事务所 关于 上海美迪西生物医药股份有限公司 法律意见书 致：上海美迪西生物医药股份有限公司 北京安理（上海）律师事务所（以下简称"本所"）接受上海美迪西生物医 药股份有限公司（以下简称"公司"）的委托，指派见证律师出席公司2024年年 度股东大会（以下简称"本次股东大会"）进行法律见证，依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）等法律、法规、规章、规范性文件及公司现行章程的规定， 就公司本次股东大会的召集、召开程序、出席会议人员的资格、表决程序等有关 事项的合法性进行了审核和见证，并出具本法律意见书。 为出具本法律意见书，本所律师出席了公司本次股东大会并审查了公司提供 的本次股东大会的各项议程及相关文件。 本所律师得到公司如下保证：公司向本所提供的文件及所作的陈述是真实、 准确、完整、有效的，一切足以影响本法律意见书的事实和文件均已向 ...

北京安理（上海）律师事务所 关于 上海美迪西生物医药股份有限公司 2024 年年度股东大会的 法律意见书 上海市长宁区长宁路 1189 号长宁来福士广场 T2 办公楼 17 层 03 单元 1703 Tower 2, Raffles City, 1189 Changning Road, Changning District, Shanghai 安理律师事务所 法律意见书 北京安理（上海）律师事务所 上海美迪西生物医药股份有限公司 2024 年年度股东大会的 法律意见书 致：上海美迪西生物医药股份有限公司 北京安理（上海）律师事务所（以下简称"本所"）接受上海美迪西生物医 药股份有限公司（以下简称"公司"）的委托，指派见证律师出席公司2024年年 度股东大会（以下简称"本次股东大会"）进行法律见证，依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）等法律、法规、规章、规范性文件及公司现行章程的规定， 就公司本次股东大会的召集、召开程序、出席会议人员的资格、表决程序等有关 事项的合法性进行了审核和见证，并出具本法律意见书。 关于 为出具本法律意见书，本所 ...

证券代码：688202 证券简称：美迪西 公告编号：2025-035 上海美迪西生物医药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 13 日 （二） 股东大会召开的地点：上海市浦东新区川大路 585 号上海美迪西生物医 药股份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 77 | | --- | --- | | 普通股股东人数 | 77 | | 2、出席会议的股东所持有的表决权数量 | 56,390,374 | | 普通股股东所持有表决权数量 | 56,390,374 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 42.5248 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 42.52 ...

证券代码：688202 证券简称：美迪西 公告编号：2025-034 上海美迪西生物医药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 具体内容详见公司分别于 2024 年 12 月 28 日、2025 年 1 月 25 日在上海证券 交易所网站（www.sse.com.cn）披露的《上海美迪西生物医药股份有限公司关于以 集中竞价方式回购股份方案的公告》（公告编号：2024-062）、《上海美迪西生物医 药股份有限公司关于以集中竞价方式回购股份的回购报告书》（公告编号： 2025-011）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应在每个月的前 3 个交易日内公告截至上月 末的回购进展情况。现将公司回购股份进展情况公告如下： 2025 年 4 月，公司通过集中竞价交易方式已累计回购公司股份 695,332 股， 占公司总股本的比例为 0.52%，回购成交的最高价为 30.04 元/股，最低价为 27.76 元/股，支付的资金总额为人民币 19,924,016.47 元（不含印花税、交易佣金等交易 费用）。截至 ...

Group 1 - Shareholders of Alade (301419.SZ) plan to reduce their holdings by no more than 1.50% within three months after 15 trading days through centralized bidding and/or block trading [1] - Shareholders of Dawi Technology (600589.SH) intend to reduce their holdings by no more than 3% within three months after 15 trading days through centralized bidding and block trading [1] - Employees of Dingzhi Technology (873593.BJ) have completed a reduction of 0.6431% of their holdings through centralized bidding [1] Group 2 - Shareholders of Aerospace Software (688562.SH) plan to reduce their holdings by no more than 1.00% through centralized bidding [2] - Shareholders of Hongqiang Co., Ltd. (002809.SZ) have completed their reduction plans, with reductions of 1%, 0.132%, and 0.021% respectively [2] - Shareholders of Huachangda (300278.SZ) plan to reduce their holdings by no more than 0.703% within three months after 15 trading days through centralized bidding [2] Group 3 - Shareholders of Liancheng CNC (835368.BJ) plan to reduce their holdings by no more than 2% within three months after 15 trading days through centralized bidding and block trading [3] - Shareholders of Meidixi (688202.SH) intend to reduce their holdings by no more than 2.23% within three months after 15 trading days through centralized bidding or block trading [3] - Shareholders of Meixin Technology (301577.SZ) plan to reduce their holdings by no more than 2.5% through centralized bidding and block trading [3] Group 4 - Shareholders of Wanda Film (002739.SZ) have completed their reduction plan, with a total reduction of 63,353,361 shares, accounting for 3.00% of the total share capital [4] - Shareholders of Xinghua New Materials (301077.SZ) plan to reduce their holdings by no more than 3% within three months after three trading days through centralized bidding and block trading [4] - Shareholders of Yinbao Shanneng (002786.SZ) have completed their reduction plan, with a total reduction of 9,912,100 shares, accounting for 2.00% of the total share capital [4] Group 5 - Shareholders of Intercontinental Oil and Gas (600759.SH) have completed their reduction plan, with a total reduction of 124,499,600 shares, accounting for 3% of the total share capital [5]

Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]